Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cognition Therapeutics Inc CGTX

Healthcare Biotechnology
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CGTX)

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

GlobeNewswire 5 days ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire 7 days ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 20, 2025

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

GlobeNewswire November 13, 2025

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

GlobeNewswire November 6, 2025

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

GlobeNewswire September 3, 2025

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

GlobeNewswire September 2, 2025

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

GlobeNewswire August 27, 2025

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire August 26, 2025
View More News ››

Opinion & Analysis (NDAQ:CGTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CGTX)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
coolfooldumbguy - August 25, 2025

Using technical analysis for this stock.

It is signalling a big upswing for shareholders this morning so BUY it already or else FOMO
coolfooldumbguy - August 13, 2025

Ok, I will start, stock closed at $2.17 5-19-23-could be ..

interesting. Different take on AD. High risk play but I could make a case for this to be a $50-$100 stock in 24 months if they can prove...
ubiquitousman - May 20, 2023
View more Bullboard ››

LaFleur Minerals Inc.

LaFleur Minerals Inc.

LaFleur Minerals Inc. explores for lithium and gold deposits in Canada. The company holds interest in the Swanson Gold ...
View More »